(Q26471859)

3

0 references

Meg Jardine

Meg J Jardine

10

0 references

Alan Cass

Alan Cass

4

0 references

Giovanni Strippoli

9

Giovanni FM Strippoli

0 references

Sankar Navaneethan

7

Sankar D Navaneethan

0 references

Sagar U Nigwekar

1

Sagar U Nigwekar

0 references

Amy Kang

2

Amy Kang

0 references

Satyarth Kulshrestha

6

Satyarth Kulshrestha

0 references

author name string

Martin P Gallagher

Cochrane Database of Systematic Reviews

5

0 references

language of work or name

English

0 references

publication date

31 May 2016

0 references

published in

0 references

issue

5

0 references

page(s)

CD004683

0 references

cites work

Atherosclerosis and folic acid supplementation trial in chronic renal failure: baseline results

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

Association of carotid intima-medial thickness and indices of arterial stiffness with cardiovascular disease outcomes in CKD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

Advanced chronic kidney disease, cardiovascular events and the effect of diabetes: data from the Atherosclerosis and Folic Acid Supplementation Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

Cardiovascular morbidity and mortality in the Atherosclerosis and Folic Acid Supplementation Trial (ASFAST) in chronic renal failure: a multicenter, randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

B vitamins and the risk of total mortality and cardiovascular disease in end-stage renal disease: results of a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

Homocysteine lowering and cognition in CKD: the Veterans Affairs homocysteine study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

Design and statistical issues in the homocysteinemia in kidney and end stage renal disease (HOST) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

Effect of the MTHFR C677T and A1298C polymorphisms on survival in patients with advanced CKD and ESRD: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

Racial differences in markers of mineral metabolism in advanced chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

Associations of plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D concentrations with death and progression to maintenance dialysis in patients with advanced kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

Low body mass index and dyslipidemia in dialysis patients linked to elevated plasma fibroblast growth factor 23.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

Adverse myocardial effects of B-vitamin therapy in subjects with chronic kidney disease and hyperhomocysteinaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

Homocysteine-lowering vitamin B treatment decreases cardiovascular events in hemodialysis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

Homocysteine-lowering vitamin B treatment decreases cardiovascular events in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

Randomized trial of folic acid for prevention of cardiovascular events in end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

Effects of folinic acid on forearm blood flow in patients with end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

Association between global leukocyte DNA methylation, renal function, carotid intima-media thickness and plasma homocysteine in patients with stage 2-4 chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

Randomized placebo-controlled trial assessing a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on plasma asymmetric dimethylarginine concentration in mild to moderate CKD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

Plasma asymmetric dimethylarginine (ADMA) concentration is independently associated with carotid intima-media thickness and plasma soluble vascular cell adhesion molecule-1 (sVCAM-1) concentration in patients with mild-to-moderate renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

Effect of a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on carotid intima-media thickness, endothelial function, and renal function in patients with mild to moderate chronic kidney disease: results from the Ant

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

Effect of over-the-counter fish-oil administration on plasma Lp(a) levels in an end-stage renal disease population

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

Omega-3 fatty acid supplementation and total homocysteine levels in end-stage renal disease patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

Does oral folic acid lower total homocysteine levels and improve endothelial function in children with chronic renal failure?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

Treatment of hyperhomocysteinemia in hemodialysis patients and renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

Pharmacological dose of vitamin B12 is as effective as low-dose folinic acid in correcting hyperhomocysteinemia of hemodialysis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

5-methyltetrahydrofolate administration is associated with prolonged survival and reduced inflammation in ESRD patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

Mesna for the treatment of hyperhomocysteinemia in hemodialysis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

Effect of dialyser membrane pore size on plasma homocysteine levels in haemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

Homocysteine lowering effect of different multivitamin preparations in patients with end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

Effect of B-vitamin therapy on progression of diabetic nephropathy: a randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

Hyperhomocysteinaemia therapy in haemodialysis patients: folinic versus folic acid in combination with vitamin B6 and B12.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

Hydroxocobalamin reduces hyperhomocysteinemia in end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

The effect of N-acetylcysteine on plasma total homocysteine levels in hemodialysis: a randomized, controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

The effect of PMMA-based protein-leaking dialyzers on plasma homocysteine levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

Glycoxidation and inflammatory markers in patients on treatment with PMMA-based protein-leaking dialyzers

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

Efficacy of folinic versus folic acid for the correction of hyperhomocysteinemia in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

Cobalamin dose regimen for maximum homocysteine reduction in end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

Comparative effects of hydroxocobalamin and cyanocobalamin on plasma homocysteine concentrations in end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

Rationale, design and baseline characteristics of a large, simple, randomized trial of combined folic acid and vitamins B6 and B12 in high-risk patients: the Heart Outcomes Prevention Evaluation (HOPE)-2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

Homocysteine lowering with folic acid and B vitamins in people with chronic kidney disease--results of the renal Hope-2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

Homocysteine-lowering therapy and risk for venous thromboembolism: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

Hopeful for a second HOPE-2 post hoc analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

Homocysteine-lowering therapy and stroke risk, severity, and disability: additional findings from the HOPE 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

Randomized clinical trial of homocysteine level lowering therapy and fractures

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

Effects of soy consumption on oxidative stress, blood homocysteine, coagulation factors, and phosphorus in peritoneal dialysis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

Effects of soy consumption on serum lipids and apoproteins in peritoneal dialysis patients: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

Effects of omega-3 fatty acids on serum lipids, lipoprotein (a), and hematologic factors in hemodialysis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

Efficacy of methylcobalamin on lowering total homocysteine plasma concentrations in haemodialysis patients receiving high-dose folic acid supplementation

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

Randomized controlled trial of the effect of short-term coadministration of methylcobalamin and folate on serum ADMA concentration in patients receiving long-term hemodialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

Increased targeting of cardiovascular risk factors in patients with chronic kidney disease does not improve atheroma burden or cardiovascular function

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

Metabolic syndrome in severe chronic kidney disease: Prevalence, predictors, prognostic significance and effects of risk factor modification

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

Effect of aggressive risk factor modification on cardiac events and myocardial ischaemia in patients with chronic kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

Vitamin B12 decreases, but does not normalize, homocysteine and methylmalonic acid in end-stage renal disease: a link with glycine metabolism and possible explanation of hyperhomocysteinemia in end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

Oral vitamin B(12) and high-dose folic acid in hemodialysis patients with hyper-homocyst(e)inemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

Randomized trial of FX high flux vs standard high flux dialysis for homocysteine clearance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

Effect of oral N-acetylcysteine treatment on plasma inflammatory and oxidative stress markers in peritoneal dialysis patients: a placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

n-3 polyunsaturated fatty acids and adiponectin in patients with end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

The content of docosahexaenoic acid in serum phospholipid is inversely correlated with plasma homocysteine levels in patients with end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

The effect of n-3 fatty acids on lipids and lipoproteins in patients treated with chronic haemodialysis: a randomized placebo-controlled intervention study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

Effects of zinc supplement on plasma homocysteine level in end-stage renal disease patients: a double-blind randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

Effects of folic acid before and after vitamin B12 on plasma homocysteine concentrations in hemodialysis patients with known MTHFR genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

Randomized, placebo-controlled trial of intramuscular vitamin B12 for the treatment of hyperhomocysteinaemia in dialysis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

Acetylcysteine reduces plasma homocysteine concentration and improves pulse pressure and endothelial function in patients with end-stage renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

Folie acid dosage for chronic hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

The antioxidant acetylcysteine reduces cardiovascular events in patients with end-stage renal failure: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

Intravenous N-acetylcysteine during haemodialysis reduces the plasma concentration of homocysteine in patients with end-stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

Mesna for treatment of hyperhomocysteinemia in hemodialysis patients: a placebo-controlled, double-blind, randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

No change in impaired endothelial function after long-term folic acid therapy of hyperhomocysteinaemia in haemodialysis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

Effect of folic acid and betaine on fasting and postmethionine-loading plasma homocysteine and methionine levels in chronic haemodialysis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

Long-term reduction of plasma homocysteine levels by super-flux dialyzers in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

Effects of fenofibrate and gemfibrozil on plasma homocysteine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

Distribution of plasma folate forms in hemodialysis patients receiving high daily doses of L-folinic or folic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

Rapid communication: L-folinic acid versus folic acid for the treatment of hyperhomocysteinemia in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

N-3 fatty acid supplementation decreases plasma homocysteine in diabetic dyslipidemia treated with statin-fibrate combination

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

The C677T methylenetetrahydrofolate reductase gene mutation does not influence cardiovascular risk in the dialysis population: results of a multicentre prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

Premature cardiovascular disease in chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

Cardiovascular and noncardiovascular mortality among patients starting dialysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

Impact of malnutrition-inflammation on the association between homocysteine and mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

Homocyst(e)ine and cardiovascular disease: a critical review of the epidemiologic evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

Folic acid supplementation to prevent adverse events in individuals with chronic kidney disease and end stage renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

Meta-analysis of B vitamin supplementation on plasma homocysteine, cardiovascular and all-cause mortality

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

The effect of folic acid based homocysteine lowering on cardiovascular events in people with kidney disease: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

A low, rather than a high, total plasma homocysteine is an indicator of poor outcome in hemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

Arterial stiffness in dialysis patients: where are we now?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

MTHFR 677C-->T polymorphism and risk of coronary heart disease: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

Relationship between homocysteine and mortality in chronic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

Homocysteine-lowering therapy does not lead to reduction in cardiovascular outcomes in chronic kidney disease patients: a meta-analysis of randomised, controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

Hyperhomocysteinemia confers an independent increased risk of atherosclerosis in end-stage renal disease and is closely linked to plasma folate and pyridoxine concentrations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

Homocysteine-lowering is not a primary target for cardiovascular disease prevention in chronic kidney disease patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

Why is homocysteine elevated in renal failure and what can be expected from homocysteine-lowering?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

B vitamins in patients with recent transient ischaemic attack or stroke in the VITAmins TO Prevent Stroke (VITATOPS) trial: a randomised, double-blind, parallel, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

Chronic kidney disease as a risk factor for cardiovascular disease and all-cause mortality: a pooled analysis of community-based studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

An MTHFR variant, homocysteine, and cardiovascular comorbidity in renal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

Homocysteine level and risk of fracture: A meta-analysis and systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

Interventions for lowering plasma homocysteine levels in dialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

Effect of Intravenous ω-3 Fatty Acid Infusion and Hemodialysis on Fatty Acid Composition of Free Fatty Acids and Phospholipids in Patients With End-Stage Renal Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

Marine n-3 fatty acids, atrial fibrillation and QT interval in haemodialysis patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

Hyperhomocysteinemia: a renal and cardiovascular risk factor?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

Influence of dialysis techniques and alternate vitamin supplementation on homocysteine levels in patients with known MTHFR genotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

7 January 2021

Folic acid therapy reduces plasma homocysteine levels and improves plasma antioxidant capacity in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

7 January 2021

High dose-B-vitamin treatment of hyperhomocysteinemia in dialysis patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

7 January 2021

Hyperhomocysteinemia in hemodialysis patients: effects of 12-month supplementation with hydrosoluble vitamins

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

7 January 2021

Treatment of hyperhomocysteinemia in end-stage renal disease.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

7 January 2021

The effect of n-3 fatty acids on heart rate variability in patients treated with chronic hemodialysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

7 January 2021

Omega-3 fatty acids supplementation does not affect serum lipids in chronic hemodialysis patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

7 January 2021

Acute effect of amino acid peritoneal dialysis solution on vascular function.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

7 January 2021

Survival advantages of obesity in dialysis patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

7 January 2021

Randomized trial of high-flux vs low-flux haemodialysis: effects on homocysteine and lipids

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

7 January 2021

Effect of multivitamins on plasma homocysteine and folate levels in patients on hemodialysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

7 January 2021

Treatment of mild hyperhomocysteinemia in renal transplant recipients versus hemodialysis patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

7 January 2021

Uremic hyperhomocysteinemia: a randomized trial of folate treatment for the prevention of cardiovascular events

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

7 January 2021

Homocysteine, the kidney, and vascular disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

7 January 2021

A controlled trial of the effect of folate supplements on homocysteine, lipids and hemorheology in end-stage renal disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

7 January 2021

Folate supplementation in peritoneal dialysis patients with normal erythrocyte folate: effect on plasma homocysteine

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

7 January 2021

Randomized trial of methylcobalamin and folate effects on homocysteine in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

7 January 2021

Propionyl-L-carnitine therapy: effects on endothelin-1 and homocysteine levels in patients with peripheral arterial disease and end-stage renal disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

7 January 2021

Effects of marine omega-3 fatty acids on serum systemic and vascular inflammation markers and oxidative stress in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

7 January 2021

Controlled comparison of L-5-methyltetrahydrofolate versus folic acid for the treatment of hyperhomocysteinemia in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

7 January 2021

Does folic acid decrease plasma homocysteine and improve endothelial function in patients with predialysis renal failure?

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

7 January 2021

Effects of folic acid and vitamin B complex on serum C-reactive protein and albumin levels in stable hemodialysis patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

7 January 2021

A randomised, controlled clinical trial evaluating changes in therapeutic efficacy and oxidative parameters after treatment with propionyl L-carnitine in patients with peripheral arterial disease requiring haemodialysis

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

7 January 2021

N-3 fatty acids as secondary prevention against cardiovascular events in patients who undergo chronic hemodialysis: a randomized, placebo-controlled intervention trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

7 January 2021

Effect of a treatment strategy consisting of pravastatin, vitamin E, and homocysteine lowering on arterial compliance and distensibility in patients with mild-to-moderate chronic kidney disease

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

7 January 2021

Neither folic nor folinic acid normalize homocysteine levels in hemodialysis patients

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

7 January 2021

Influence of hemodialysis membrane permeability on serum levels of advanced glycation end products (AGEs) and homocysteine metabolites.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

7 January 2021

Intravenous N-acetylcysteine during hemodialysis reduces asymmetric dimethylarginine level in end-stage renal disease patients.

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

7 January 2021

Influence of a supplementation with vitamins on cardiovascular morbidity and mortality in patients with end-stage renal disease: design and baseline data of a randomized clinical trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD004683.PUB4

7 January 2021